PMID- 34584995
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230921
IS  - 2405-805X (Electronic)
IS  - 2405-805X (Linking)
VI  - 6
IP  - 4
DP  - 2021 Dec
TI  - Antidiabetic effect of an engineered bacterium Lactobacillus plantarum-pMG36e 
      -GLP-1 in monkey model.
PG  - 272-282
LID - 10.1016/j.synbio.2021.09.009 [doi]
AB  - Glucagon-like peptide-1 (GLP-1) reduces postprandial hyperglycaemia, but its 
      short half-life inhibits clinical application. The aim of the current study was 
      to evaluate the treatment efforts of an engineered strain, Lactobacillus 
      plantarum-pMG36e-GLP-1 (L. plantarum-pMG36e-GLP-1), that continuously expresses 
      GLP-1 in spontaneous type 2 diabetes mellitus (T2DM) monkeys. After 7 weeks of 
      oral supplementation with L. plantarum-pMG36e-GLP-1, the fasting blood glucose 
      (FPG) of monkeys was significantly (p < 0.05) reduced to a normal level and only 
      a small amount of weight was lost. The results of metagenomic sequencing showed 
      that L. plantarum-pMG36e-GLP-1 caused a substantial (p < 0.05) reduction in the 
      intestinal pathogen Prevotella and marked enhancement of butyrate-producing 
      Alistipes genera. According to the functional analysis using Kyoto Encyclopaedia 
      of Genes and Genomes (KEGG) pathways, 19 metabolism-related pathways were 
      significantly enriched in T2DM monkeys after treatment with L. 
      plantarum-pMG36e-GLP-1. LC-MS faecal metabolomics analysis found 41 significant 
      differential metabolites (11 higher and 30 lower) in monkeys after treatment 
      pathways linked to the metabolism of cofactors and vitamins were the most 
      relevant. The present study suggests that L. plantarum-pMG36e-GLP-1 had an impact 
      on the gut microbial composition and faecal metabolomic profile in spontaneous 
      T2DM monkeys and may be a novel candidate for diabetes treatment.
CI  - (c) 2021 The Authors.
FAU - Luo, Jie
AU  - Luo J
AD  - School of Public Health and Key Laboratory of Preventive Medicine, Nanchang 
      University, Nanchang, 330031, China.
FAU - Zhang, Hongfei
AU  - Zhang H
AD  - Institute of Life Sciences, Nanchang University, Nanchang, 330031, China.
FAU - Lu, Jiachen
AU  - Lu J
AD  - School of Queen Mary, Nanchang University, Nanchang, 330031, China.
FAU - Ma, ChaoLin
AU  - Ma C
AD  - Institute of Life Sciences, Nanchang University, Nanchang, 330031, China.
FAU - Chen, Tingtao
AU  - Chen T
AD  - National Engineering Research Center for Bioengineering Drugs and the 
      Technologies, Institute of Translational Medicine, The First Affiliated Hospital, 
      Nanchang University, 1299 Xuefu Road, Honggu District, Nanchang, 330031, PR 
      China.
LA  - eng
PT  - Journal Article
DEP - 20210917
PL  - China
TA  - Synth Syst Biotechnol
JT  - Synthetic and systems biotechnology
JID - 101694371
PMC - PMC8455315
OTO - NOTNLM
OT  - Faecal metabolomics
OT  - Gut microbiome
OT  - L. plantarum-pMG36e-GLP-1
OT  - T2DM
COIS- None declared.
EDAT- 2021/09/30 06:00
MHDA- 2021/09/30 06:01
PMCR- 2021/09/17
CRDT- 2021/09/29 06:58
PHST- 2021/07/05 00:00 [received]
PHST- 2021/08/12 00:00 [revised]
PHST- 2021/09/13 00:00 [accepted]
PHST- 2021/09/29 06:58 [entrez]
PHST- 2021/09/30 06:00 [pubmed]
PHST- 2021/09/30 06:01 [medline]
PHST- 2021/09/17 00:00 [pmc-release]
AID - S2405-805X(21)00052-1 [pii]
AID - 10.1016/j.synbio.2021.09.009 [doi]
PST - epublish
SO  - Synth Syst Biotechnol. 2021 Sep 17;6(4):272-282. doi: 
      10.1016/j.synbio.2021.09.009. eCollection 2021 Dec.